Augmentation treatment for α1 antitrypsin deficiency may slow the progression of emphysema, a study in the Lancet shows. Findings from observational and cohort studies had shown that the rate of FEV1 loss was slower in individuals with α1 antitrypsin deficiency who received α1 proteinase inhibitor (A1PI) augmentation treatment compared to those who did not. But ...
Already a member?
Enter your email to keep reading.